Quarterly ResultMay 7, 2026, 07:12 AM
Akebia Q1 Net Loss $9.1M; Vafseo Revenue Up 31.7%
AI Summary
Akebia Therapeutics reported a net loss of $9.1 million for the first quarter of 2026, a significant shift from a net income of $6.1 million in Q1 2025. Total revenues decreased to $53.5 million, primarily due to lower Auryxia sales, despite Vafseo net product revenues growing to $15.8 million. The company also highlighted commercial growth for Vafseo, with a 60% increase in patients, and progress in its kidney disease pipeline, including ongoing Phase 2 trials for praliciguat and plans for new studies for AKB-097 and AKB-9090.
Key Highlights
- Q1 2026 net loss was $9.1 million, compared to net income of $6.1 million in Q1 2025.
- Total revenues decreased to $53.5 million in Q1 2026 from $57.3 million in Q1 2025.
- Vafseo net product revenues grew 31.7% to $15.8 million in Q1 2026.
- Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025.
- Research and development expenses increased to $14.8 million in Q1 2026 from $9.8 million in Q1 2025.
- Cash and cash equivalents were $162.6 million as of March 31, 2026.
- Patient enrollment continues in praliciguat Phase 2 clinical trial in FSGS.
- Akebia expects topline data from VOCAL Phase 3b trial in Q4 2026 and VOICE Phase IV trial in early 2027.